Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in newly diagnosed high-grade and unfavorable low-grade glioma
NCT00124657Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2005
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib in glioma and low-grade glioma (LGG), sponsored by St. Jude Children's Research Hospital. Started Mar 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
gliomalow-grade glioma (LGG)
Beyond the preview
Go deeper on NCT00124657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124657.